查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081997

腦膜炎雙球菌疫苗市場：全球市場預測（依疫苗類型、年齡層、劑型、通路、最終用戶和適應症分類）－2026-2032年

Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦膜炎雙球菌疫苗市場規模將達到 137.4 億美元，年複合成長率為 11.02%。

主要市場統計數據
基準年 2025 66億美元
預計年份：2026年 71.6億美元
預測年份 2032 137.4億美元
複合年成長率 (%) 11.02%

執行摘要：腦膜炎雙球菌疫苗市場展望

腦膜炎雙球菌疫苗的市場趨勢主要受公共衛生優先事項——預防侵襲性腦膜炎雙球菌病菌感染——的驅動。這種由腦膜炎奈瑟菌引起的感染疾病是一種快速進展的感染疾病，可導致腦膜炎、敗血症、長期併發症，甚至死亡。根據世界衛生組織（世衛組織）統計，A、B、C、W、X 和 Y 血清型佔全球病例的大多數，因此涵蓋多種血清型是腦膜炎雙球菌疫苗接種策略的核心。

將重塑疫苗格局的變革性變化

市場正從被動的疫情控制轉向預防性的、基於生命週期的免疫接種。儘管高所得國家仍然依賴青少年的MenACWY疫苗接種計劃和針對特定人群的MenB疫苗，但在非洲腦膜炎帶國家引入MenA結合疫苗後，大規模常規免疫接種的有效性已得到證實。這是一項獲得世衛組織認可的干預措施，已顯著降低了A型腦膜炎疫情的爆發。

人工智慧對腦膜炎雙球菌疫苗的累積影響

人工智慧（AI）正累積成為腦膜炎球菌疫苗研發、監測、生產和上市各階段的驅動力。在研究領域，AI驅動的抗原篩檢、蛋白質結構建模和生物資訊學能夠優先篩選針對流行活動波動較大的血清群（例如B群和X群）的候選疫苗。在藥物安全監測和流行病學方面，機器學習正在加速從基因組監測、實驗室報告、不利事件資料庫和集體爆發資訊系統中識別訊號。

關鍵區域視角下的全球腦膜炎雙球菌疫苗需求

亞太地區人口基數大規模，腦膜炎雙球菌疾病的流行病學情況因地域而異，疫苗生產能力不斷提升，且免疫規劃成熟度有差異。澳洲已製定青少年和基於風險因素的腦膜炎球菌疫苗接種政策，而日本和韓國則擁有健全的監管和監測體系。中國正在擴大國內疫苗生產能力並完善公共衛生免疫體系，印度仍然是主要的疫苗生產和採購中心，日益重視青少年、機構和旅遊相關的健康保護。

針對特定群體在政策、採購和市場進入的關鍵見解

東南亞國協由於成員國在免疫接種計畫、私部門採納率、醫療保健資金和疾病監測能力方面存在顯著差異，因此存在著多種機會。雖然都市區民營市場、國際學校、職業健康和旅行醫學管道支撐著需求，但更廣泛的公眾採納取決於當地疾病負擔、價格承受能力、採購優先事項以及低溫運輸發展等方面的實證數據。海灣合作理事會（GCC）國家的特點是其與旅行相關的免疫接種政策、高額的醫療保健投資，以及沙烏地阿拉伯的朝覲要求在維持公眾對MenACWY疫苗接種的認知和依從性方面所發揮的作用。

來自塑造競爭策略的關鍵國家的洞見

在美國，疾病管制與預防中心（CDC）建議對青少年進行常規免疫接種（包括加強劑），並對年輕成人進行腦膜炎球菌B群疫苗的接種，採用協作式臨床決策，從而在兒童、高校和高風險環境中建立起系統性的需求基礎。在加拿大，各省和地區採用不同的免疫接種計劃，導致不同地區的接種途徑和時間安排有差異。同時，在墨西哥和巴西，除了考慮公共部門的優先順序外，還需考慮民營市場需求、旅行相關需求以及應對感染疾病疫情的措施。

為行業領導者提供的實用建議

行業領導者應優先考慮能夠證明產品在實際應用中的有效性、保護持續時間、相關年齡層的免疫抗原性、適用情況下的群體免疫效應以及在普通人群和高危險群中的安全性的證據包。市場准入團隊需要符合國家技術諮詢小組標準、醫療技術評估要求、疫情應對方案、預算影響要求以及實施可行性的國別特定文件。

調查方法和證據

調查方法基於結構化的二手資料研究，透過三角驗證的方式整合了世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）、國家免疫規劃、監管機構、同行檢驗文獻、公共衛生監測資料庫、衛生技術評估（HTA）出版物以及公共採購研究途徑。研究重點關注檢驗的流行病學數據、疫苗政策、已批准的適應症、血清群覆蓋範圍、安全性監測以及已記錄的公共衛生實踐。

結論：腦膜炎雙球菌疫苗的策略性展望

目前，腦膜炎雙球菌疫苗的推廣應用正朝著更廣泛的預防、更完善的監測和更具針對性的政策導向接種策略發展。儘管在許多國家，腦膜炎雙球菌感染的發生率較低，但侵襲性腦膜炎雙球菌病菌感染可能迅速發展為重症，因此接種疫苗是一項至關重要的公共衛生干預措施，尤其對於青少年、特定項目覆蓋的嬰幼兒、旅行者、相關人員、大學生、疫情暴發地區以及免疫力缺乏人群而言。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 腦膜炎雙球菌疫苗市場：依疫苗類型分類

  • 組合型
  • 多醣
  • 蛋白質次單元

第8章 腦膜炎雙球菌疫苗市場：依年齡層別分類

  • 青春期
  • 成人
  • 老年人
  • 兒童

第9章 腦膜炎雙球菌疫苗市場：以劑型分類

  • 多劑量型
  • 單一劑量

第10章 腦膜炎雙球菌疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 腦膜炎雙球菌疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構
  • 疫苗接種中心

第12章 腦膜炎雙球菌疫苗市場：依適應症分類

  • 應對集體爆發
  • 常規疫苗接種
  • 旅行者疫苗接種

第13章 腦膜炎雙球菌疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 腦膜炎雙球菌疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦膜炎雙球菌疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bharat Biotech Ltd.
  • Bio-Med Private Ltd
  • Biological E. Limited
  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Limited
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-430D42AA101A

The Meningococcal Vaccines Market is projected to grow by USD 13.74 billion at a CAGR of 11.02% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.60 billion
Estimated Year [2026] USD 7.16 billion
Forecast Year [2032] USD 13.74 billion
CAGR (%) 11.02%

Executive Summary: Meningococcal Vaccines Market Outlook

The meningococcal vaccines landscape is anchored by the public health priority of preventing invasive meningococcal disease, a fast-progressing infection caused by Neisseria meningitidis that can lead to meningitis, septicemia, long-term disability, and death. According to the World Health Organization, serogroups A, B, C, W, X, and Y account for most disease globally, making broad serogroup coverage central to meningococcal immunization strategy.

Demand is shaped by national immunization programs, outbreak response, travel requirements, adolescent vaccination, military and university policies, and protection for high-risk patients, including people with complement deficiencies, asplenia, or immunosuppression. Conjugate MenACWY vaccines, MenB vaccines, and emerging pentavalent approaches are driving a landscape defined by clinical evidence, regulatory scrutiny, procurement reliability, cold-chain performance, and measurable population-level impact.

Transformative Shifts Reshaping the Vaccine Landscape

The market is shifting from reactive outbreak control toward preventive, lifecycle-based immunization. High-income countries continue to rely on adolescent MenACWY programs and targeted MenB use, while countries in the African meningitis belt have demonstrated the value of mass vaccination and routine immunization after MenA conjugate vaccine deployment, a WHO-recognized intervention associated with major reductions in serogroup A epidemics.

Product strategy is also evolving. Vaccine developers are investing in broader serogroup coverage, simplified schedules, thermostability improvements, and evidence packages that support national immunization technical advisory group recommendations. At the same time, procurement agencies increasingly evaluate not only price per dose but also supply continuity, cold-chain performance, real-world effectiveness, safety monitoring, and compatibility with existing infant, adolescent, travel, and high-risk immunization visits.

Cumulative Impact of Artificial Intelligence on Meningococcal Vaccines

Artificial intelligence is becoming a cumulative accelerator across meningococcal vaccine discovery, surveillance, manufacturing, and market access. In research, AI-enabled antigen screening, protein-structure modeling, and bioinformatics can help prioritize candidates for serogroups with variable epidemiology, including serogroup B and X. In pharmacovigilance and epidemiology, machine learning supports faster signal detection from genomic surveillance, laboratory reports, adverse event databases, and outbreak intelligence systems.

Commercially, AI improves demand planning, inventory allocation, tender preparation, cold-chain risk management, and scenario modeling for outbreak response. Its greatest value is not replacing clinical validation or public health judgment, but compressing decision cycles while maintaining regulatory-grade evidence, explainability, data privacy, cybersecurity, and human oversight in meningococcal vaccine programs.

Key Regional Insights Across Global Meningococcal Vaccine Demand

Asia-Pacific combines large birth cohorts with uneven meningococcal epidemiology, expanding vaccine manufacturing capacity, and differing levels of program maturity. Australia has established adolescent and risk-based meningococcal vaccination policies, Japan and South Korea maintain strong regulatory and surveillance infrastructure, China is expanding domestic vaccine capability and public immunization capacity, and India remains a major vaccine manufacturing and procurement hub with growing attention to adolescent, institutional, and travel health protection.

North America is characterized by mature recommendations, strong public and private reimbursement channels, and defined adolescent vaccination pathways, especially in the United States and Canada. Europe remains policy-driven and heterogeneous, with European regulatory coordination and national immunization technical advisory groups shaping schedules for MenACWY and MenB vaccination. Latin America shows selective public program adoption and outbreak-driven demand in countries such as Brazil and Mexico, where private-sector access also supports uptake. The Middle East is strongly influenced by Hajj and Umrah requirements for quadrivalent meningococcal vaccination, making travel-linked compliance a major demand driver. Africa remains central to global meningitis prevention because the meningitis belt carries the world's highest epidemic risk, and WHO's roadmap to defeat meningitis by 2030 continues to support surveillance, outbreak preparedness, and broader vaccine access.

Key Group Insights for Policy, Procurement, and Market Access

ASEAN countries present diverse opportunities because immunization schedules, private-sector uptake, healthcare financing, and disease surveillance capacity vary substantially across member states. Urban private markets, international schools, occupational health, and travel medicine channels support demand, while broader public adoption depends on local disease-burden evidence, affordability, procurement priorities, and cold-chain readiness. The GCC is distinguished by travel-linked vaccination policy, high healthcare investment, and the role of Saudi Arabia's pilgrimage requirements in sustaining awareness and compliance for MenACWY vaccination.

The European Union offers a robust regulatory, pharmacovigilance, and health technology assessment environment, but meningococcal vaccine adoption remains nationally determined according to epidemiology, budget priorities, and program design. BRICS countries combine large populations, domestic manufacturing ambitions, expanding immunization infrastructure, and rising interest in vaccine security. G7 markets drive clinical evidence standards, premium product uptake, adolescent vaccination policy, and pharmacovigilance expectations, while NATO countries create additional institutional demand through military readiness programs where meningococcal protection is relevant for recruits and personnel living or training in close-quarter settings.

Key Country Insights Shaping Competitive Strategy

In the United States, CDC guidance supports routine MenACWY vaccination for adolescents with a booster dose and shared clinical decision-making for MenB vaccination in young adults, creating a structured demand base across pediatric, college, and high-risk settings. Canada uses provincial and territorial schedules, resulting in differences in access and timing across jurisdictions, while Mexico and Brazil combine public-sector prioritization with private market demand, travel needs, and outbreak response considerations.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent evidence-led markets with varying MenB and MenACWY policies, reflecting national assessments of disease burden, cost-effectiveness, infant and adolescent schedules, and outbreak management. Russia's demand reflects national epidemiology, procurement priorities, regulatory requirements, and domestic supply considerations. China and India are strategically important because of population scale, immunization infrastructure, and vaccine manufacturing capacity. Japan, Australia, and South Korea offer sophisticated regulatory environments, high healthcare quality expectations, and strong potential for targeted adolescent, travel, university, military, and risk-group vaccination strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate real-world effectiveness, duration of protection, immunogenicity across relevant age groups, herd effects where applicable, and safety in routine and high-risk populations. Market access teams need country-specific dossiers that align with national technical advisory group criteria, health technology assessment expectations, outbreak-response protocols, budget impact requirements, and implementation feasibility.

Vaccine manufacturers should also strengthen supply resilience through diversified antigen sourcing, validated cold-chain controls, robust quality systems, and transparent shortage communication. Strategic growth will favor organizations that pair broader serogroup coverage with affordable procurement models, digital demand forecasting, post-marketing evidence generation, and partnerships with public health agencies, universities, military health systems, travel medicine networks, and outbreak surveillance programs.

Research Methodology and Evidence Base

Research methodology is developed using a structured secondary research approach that triangulates information from the World Health Organization, U.S. Centers for Disease Control and Prevention, national immunization schedules, regulatory agencies, peer-reviewed literature, public health surveillance databases, health technology assessment publications, and public procurement references. Emphasis is placed on verified epidemiology, vaccine policy, approved indications, serogroup coverage, safety monitoring, and documented public health practices.

The analysis compares regional demand drivers, policy adoption, product coverage, access barriers, procurement models, outbreak response practices, and innovation signals. Insights are validated for consistency across credible public sources and presented without unsupported market-size, market-share, or market-forecast claims.

Conclusion: Strategic Outlook for Meningococcal Vaccines

The meningococcal vaccines landscape is moving toward broader protection, smarter surveillance, and more policy-specific access strategies. While disease incidence can be low in many countries, the rapid severity of invasive meningococcal disease keeps vaccination a high-value public health intervention, especially for adolescents, infants in selected programs, travelers, military populations, university students, outbreak settings, and immunocompromised individuals.

Winning strategies will depend on clinical differentiation, reliable supply, affordability, regulatory readiness, and the ability to translate epidemiological evidence into policy action. Stakeholders that combine scientific credibility with regional execution, transparent safety evidence, and resilient procurement support are best positioned to strengthen sustainable access to meningococcal vaccination.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Meningococcal Vaccines Market, by Vaccine Type

  • 7.1. Conjugate
  • 7.2. Polysaccharide
  • 7.3. Protein Subunit

8. Meningococcal Vaccines Market, by Age Group

  • 8.1. Adolescent
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Meningococcal Vaccines Market, by Formulation

  • 9.1. Multi Dose
  • 9.2. Single Dose

10. Meningococcal Vaccines Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Meningococcal Vaccines Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Vaccination Centers

12. Meningococcal Vaccines Market, by Indication

  • 12.1. Outbreak Response
  • 12.2. Routine Prophylactic
  • 12.3. Traveler Immunization

13. Meningococcal Vaccines Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Meningococcal Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Meningococcal Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Astellas Pharma Inc.
  • 17.2. AstraZeneca PLC
  • 17.3. Bharat Biotech Ltd.
  • 17.4. Bio-Med Private Ltd
  • 17.5. Biological E. Limited
  • 17.6. Chongqing Zhifei Biological Products Co., Ltd.
  • 17.7. GlaxoSmithKline PLC
  • 17.8. Incepta Pharmaceuticals Ltd.
  • 17.9. Merck & Co., Inc.
  • 17.10. Novartis AG
  • 17.11. Pfizer Inc.
  • 17.12. PT Bio Farma
  • 17.13. Sanofi S.A.
  • 17.14. Serum Institute of India Pvt. Ltd.
  • 17.15. Taj Pharmaceuticals Limited
  • 17.16. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POLYSACCHARIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POLYSACCHARIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POLYSACCHARIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADOLESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADOLESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADOLESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OUTBREAK RESPONSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OUTBREAK RESPONSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OUTBREAK RESPONSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ROUTINE PROPHYLACTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ROUTINE PROPHYLACTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ROUTINE PROPHYLACTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRAVELER IMMUNIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRAVELER IMMUNIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRAVELER IMMUNIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 148. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)